Fibroblast growth factor 23 in acute kidney injury
- 1 July 2014
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 23 (4) , 340-345
Abstract
To review emerging literature on changes in fibroblast growth factor 23 (FGF23) levels in the setting of acute kidney injury. studies suggest that FGF23 levels are elevated in patients with acute kidney injury, and correlate with increased risk of death or need for dialysis (in adults) or prolonged ventilation time and higher fluid gain (in children). Animal work shows that the etiology behind this FGF23 increase is multi-factorial and includes increased production in bone and decreased clearance, but not vitamin D or PTH-activated pathways. Interestingly, FGF23 levels were found to be mildly elevated even in hospitalized patients without kidney injury, although this observation may be limited to only c-terminal FGF23 fragments. The prognostic implications of an elevated FGF23 value in patients with acute kidney injury need to be confirmed in larger cohorts and evaluated for long-term outcomes such as development of new CKD or CKD progression, as well as cardiovascular disease, similar to studies of FGF23 in the prevalent CKD population. FGF23 levels are elevated in patients with AKI and are associated with morbidity and mortality is small human studies. Mechanistic work in animals suggests that the elevation is independent of PTH or vitamin D-signaling pathways. Much work remains to understand the physiology behind FGF23 elevation and the long-term effects of FGF23 in AKI.Keywords
This publication has 43 references indexed in Scilit:
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in miceProceedings of the National Academy of Sciences, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series studyAnnals of Intensive Care, 2011
- Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically ActiveThe Journal of Clinical Endocrinology & Metabolism, 2010
- Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney diseaseBone, 2009
- Defective O-Glycosylation due to a Novel Homozygous S129P Mutation Is Associated with Lack of Fibroblast Growth Factor 23 Secretion and Tumoral CalcinosisThe Journal of Clinical Endocrinology & Metabolism, 2009
- Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney DiseaseCirculation, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008